MarketLens

What Did D3 Bio Present at ASCO 2026 for Elisrasib

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Did Ascentage Pharma Present at ASCO 2026

3 months ago

Is D3 Bio's Elisrasib a Game-Changer in KRAS G12C NSCLC

3 months ago

What Makes Elisrasib's ASCO 2026 Data So Significant

3 months ago

What Makes Akeso's ASCO 2026 Plenary Session So Crucial

3 months ago

HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026

Summit Therapeutics noted that Akeso's Phase III HARMONi-GI1 trial of ivonescimab plus chemotherapy in first-line advanced biliary tract cancer will be presented at ESMO 2026's Presidential Symposium ...

SMMT

Stock News•1 months ago

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology's 4th Summit on Breast Cancer

LeonaBio will present lasofoxifene data at Dava Oncology's 4th Summit on Breast Cancer, August 18-22 in Kona, Hawaii, highlighting its use in ER+, HER2-negative, ESR1-mutated metastatic breast cancer.

DAVA

Stock News•2 months ago

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Erasca's ERAS-0015 showed 57% uORR in 2L KRAS G12X pancreatic cancer at 32 mg QD RDE, with 100% median relative dose intensity. Company plans registration-enabling lung cancer trial in H1 2027 and Pha...

ERAS